Close Menu

NEW YORK (360Dx) – Rosetta Genomics said that it recorded $330,000 in revenues for the RosettaGX Reveal thyroid miRNA classifier during October, which would represent a $4 million annual revenue run rate. The test classifies indeterminate thyroid nodules. The company said the revenue ramp is partly attributable to record commercial collections driven by increased sample volumes and higher per-claim payments. The test recorded $860,000 in revenues during the third quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.